INTRODUCTION

B
z-423 is a 1,4-benzodiazepine that potently suppresses disease in autoimmune mice by selectively killing pathogenic lymphocytes.
1,2 Affinity-based screening of a phage-display human cDNA expression library identified the oligomycin-sensitivity conferring protein (OSCP), a component of the mitochondrial F 1 F 0 -ATPase, as the molecular target for Bz-423. 3 Binding of Bz-423 to the OSCP in the context of intact enzyme inhibits both synthesis and hydrolysis of ATP. 3, 4 Consistent with modulation of F 1 F 0 -ATPase activity, Bz-423 increases the generation of superoxide from the mitochondrial respiratory chain and this reactive oxygen species, rather than NMR Studies of an Immunomodulatory Benzodiazepine Binding to its Molecular Target on the Mitochondrial F 1 F 0 -ATPase Additional Supporting Information may be found in the online version of this article.
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ABSTRACT:
Bz-423 is an inhibitor of the mitochondrial changes in ATP concentration, is the signal that initiates apoptosis.
5,6
The OSCP is a 213 amino acid long protein (including the mitochondrial leader sequence) that is conserved among mammals and is not present in other ATPases. 7 The OSCP along with subunits b, d, and F 6 form the peripheral stalk in mammalian F 1 F 0 -ATPases. 8 The stalk links the integral membrane F 0 component of the enzyme with its soluble catalytic F 1 domain, which is located in the mitochondrial matrix. The peripheral stalk is believed to act as a stator, holding the F 1 a 3 b 3 hexamer static while the central stalk (cdec 10 ) rotates. 9, 10 To function properly, the stalk subunits must act in concert with one another; while the peripheral stalk subunits do not need to move in relation to one another during catalysis, disrupting the connections between the subunits disrupts coupling between F 0 and F 1 . 11 In addition, the stalk must be anchored at each end for proper function: the transmembrane domain of subunit b holds the stalk in the mitochondrial membrane, while the N-terminal end of the OSCP sits on top of the a 3 b 3 hexamer with the C-terminus protruding almost 100 Å along the surface of F 1 towards F 0 .
12
The N-terminal tails of the a-subunits are critical for binding to OSCP. 13 The structure of a 134-amino acid long N-terminal fragment of the d-subunit from E. coli, the bacterial homolog of the bovine OSCP, has been studied by NMR spectroscopy. 14 The protein adopts a 6-helix bundle with a disordered C-terminus. NMR studies using the N-terminal domain of the bovine OSCP (OSCP-NT, residues 1-120) reveals a similar fold. 15, 16 Binding experiments with peptide fragments from the N-termini of F 1 a-subunits suggests that the interaction site on OSCP-NT comprises a hydrophobic groove between helices I and V. Hence, this interface, which is essential for the rotary mechanism of the enzyme, probably consists of helix-helix interactions. Because Bz-423 does not bind at the active site of enzyme, we hypothesized that it may bind at, or near the F 1 -OSCP interface where it can perturb one or more of the conformational transitions associated with the rotary (bindingchange) mechanism of catalysis. 4 To gain support for this hypothesis, we studied the binding of water soluble Bz-423 analogs ( Figure 1 ) with OSCP constructs representing amino acids 1-120 and 1-145 by NMR spectroscopy using chemical shift perturbation and cross-relaxation experiments to localize the binding site. Our data identified a recognition site near the F 1 -OSCP interface and a conformational change in the protein upon drug binding. Collectively, these data suggest that Bz-423 like inhibitors may function in an allosteric manner inducing a conformational change that hinders catalysis.
MATERIALS AND METHODS
Small Molecules Ligands
Benzodiazepines 1 and 2 were synthesized and characterized as previously described. 15 Samples of both compounds used in the NMR titration experiments were [95% pure.
Plasmid Construction
A 360-base-pair long insert encoding a truncated bovine OSCP, containing amino acids 1-120, was prepared via PCR using forward (5 0 -CACCATGTTTGCCAAGCTTGTGAGGCC-3 0 ) and reverse (5 0 -CTA AACTGTGCATGGTACTTCTCC-3 0 ) oligonucleotide primers (25 lM each) in the presence of dNTPs (0.5 mM), pOSCP (1 ng), PFU Turbo DNA polymerase (3-5 U; Stratagene, La Jolla, CA), and 13 PFU Turbo DNA polymerase buffer. PCR conditions consisted of 30 s at FIGURE 1 Chemical structure of (a) Bz-423 and the molecules used in this study: (2) . Protons of 1 that were saturated in cross-relaxation experiments are labeled. Based on prior structure-reactivity studies as a guide, 1 was designed to replace the critical phenolic proton with an ammoninum group to enhance aqueous solubility. The activity of 1 in enzyme and cellular assays is comparable. Removing the naphthyl group in 2 abolishes all activity against the enzyme.
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, 30 s annealing at 558C, and a 1 min extension at 728C for 31 cycles. 17 A 435-base-pair long insert encoding a truncated bovine OSCP containing amino acids 1-145 was prepared in a similar manner using the same forward oligonucleotide primer as above together with a reverse (5 0 -CTGGCCTTTACTTAGGAAGCTCTTCAGG-3 0 ) oligonucleotide primer. The PCR products were purified using a Qiagen (Valencia, CA) PCR Clean Up kit following the manufacturer's instructions. Both inserts were cloned into expression vectors provided in the TOPO 10 kit following the manufacture's instructions (Invitrogen, Carlsbad, CA). The OSCP 1-120 insert was ligated into pCRT7/NT-TOPO that contains both an Express TM Epitope coding sequence and a hexa-his tag, placing the OSCP 1-120 coding region C-terminal to these sequences. The OSCP 1-145 insert was ligated into pCRT7/CT-TOPO, which contains both a V5 Epitope coding sequence and a hexa-his tag, placing the OSCP 1-145 coding region N-terminal to these sequences. Thus, OSCP120 contains an N-terminal hexa-his tag connected by the linker sequence GMASMT-GGQQMGRDLYDDDDKDPTL, while the OSCP145 construct contains a C-terminal hexa-his tag connected by the linker sequence KGNSKLEGKPIPNPLLGLDSTRTG. Primary structures for all OSCP constructs are shown in Supporting Information Figure S1 . Ligation products were transformed into TOP-10 cells and selected on LBampicillin (50 lg/mL) plates. Colonies were screened for inserts via PCR using mini-prep plasmid DNA and both the forward and reverse T7 primers. The presence of the correct inserts was confirmed by automated DNA sequencing (Sequencing Core Facility, University of Michigan, Ann Arbor, MI).
Growth and Expression of OSCP Constructs
OSCP constructs pCRT7/NT-OSCP120 and pCRT7/CT-OSCP145 were transformed into One Shot BL21(DE3) pLysS (Invitrogen, Carlsbad, CA) using the manufacturer's procedure. Individual colonies were picked immediately to inoculate 1-10 mL LB overnight cultures supplemented with ampicillin (200 lg/mL). Cultures were incubated at 378C with rotary shaking at 250 rpm. One-liter cultures containing either C) media (Spectra Stable Isotopes, Columbia, molecular dynamics (MD)), were supplemented with ampicillin (200 lg/mL) and inoculated with the overnight culture. Cultures were grown at 378C with rotary shaking at 250 rpm until A 595 reached 0.6-1 (Spectra 9-dCN required double the growth time compared to the other media) at which point cultures were removed to 48C while the rotary shaker temperature was brought down to 208C using a heat exchanger over a period of 1 h. IPTG was added to a final concentration of 0.02 mM. Growth and expression continued for 20 h at 208C. Cell pastes were harvested via centrifugation in a Beckman JLA8.1 at 6000g for 10 min at 48C. Cell pastes were resuspended in ice-cold Nickel NTA buffer (25 mL; 50 mM Tris-HCl pH 8, 300 mM NaCl, 0.001% phenylmethanesulfonyl fluoride, and Roche Complete protease inhibitors w/o EDTA as per manufacturers instruction). The suspension was transferred to a 50 mL Falcon tube on ice and stored at -808C.
Purification of OSCP 120NT (His Tag) and OSCP 145CT (His Tag)
Cell paste was thawed at room temperature and placed immediately on ice. The suspension was transferred to a 50 mL beaker on ice and sonicated using the standard horn (set at output 5 8.5) for 6 20-s long intervals between which was a 2-min long rest on ice to dissipate heat. After sonication, the mixture was transferred to two Beckman JA25.5 centrifuge tubes and centrifuged at 21,000 rpm at 48C for 45 min. The soluble extract was loaded (0.5 mL/min) onto a Ni-NTA affinity column (1 cm diameter 3 5 cm long) equilibrated in Nickel NTA Buffer at 48C. The column was washed with Nickel NTA Buffer-25 mM imidazole (25 mL), and protein was eluted with Nickel NTA Buffer-250 mM imidazole (25 mL). Fractions of about 1 mL were collected and those from fractions 3-14 were direct placed into snakeskin dialysis tubing (7000 MWCO, Pierce, Rockville, IL) immersed in of OSCP Buffer (4 L; 50 mM Tris-Cl pH 8, 30 mM NaCl, 1 mM EDTA, 5 mM b-mercaptoethanol). Complete protease inhibitors (with or without EDTA) were added following the manufacturer's instructions, directly to the fractions in the dialysis bag. Following overnight dialysis at 48C with stirring, the dialysate was cleared by centrifugation using a Beckman JA 25.5 rotor for 20 min at 21,000 rpm and 48C. The clarified extract was loaded into a Ä KTA prime super loop (50 mL) at 48C and injected at 1.3 mL/min onto a 5 mL HiTrap SpHP column (Pharmacia) equilibrated in at least five volumes of modified OSCP Buffer (50 mM Tris-Cl pH 8, 30 mM NaCl, 1 mM EDTA, 0.001% phenylmethanesulfonyl fluoride, Roche Complete protease inhibitors w/o EDTA, 5 mM b-mercaptoethanol; MOB) at 48C. The column was washed with two bed volumes of the same buffer and then eluted with a 75 mL linear gradient (MOB and MOB 1 500 mM NaCl) at 1 mL/ min while collecting 1 mL fractions. OSCP 120NT eluted in a sharp band centered around 250 mM NaCl, while OSCP 145CT eluted in a similar manner at 280 mM NaCl.
NMR Spectroscopy
All NMR experiments were performed at 258C unless indicated otherwise using an Avance Bruker 600 MHz spectrometer equipped with a 5 mm triple-resonance cryogenic probe. NMR spectra were processed and analyzed using NMRPipe and SPARKY 3. Figure  S2 ). 20 The OSCP120 resonances in OSCP145 were assigned by overlaying spectra and using standard triple resonance experiments on a doubly labeled ( 
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Cross-relaxation experiments were performed at 148C to improve cross-relaxation efficiency by modifying a 2D 1 H-15 N HSQC experiment from the Bruker pulse program library (hsqcfpf3gpphwg). 21 A 1.8 s adiabatic Wurst pulse was applied following a predelay of 1.4 s for saturating one of three different ligand proton resonances (protons 7, 10, and 24; Figure 1 ) with a total saturation bandwidth of 30 Hz. 22 An additional reference experiment was also recorded with off-resonance (-50 ppm) saturation. Each experiment required 23 h of acquisition time. Peak intensity errors were calculated using NMRPipe and ranged between 4% and 19%. 18, 19 Cross-relaxation intensity ratios were calculated by taking the ratio of peak intensities measured with on-resonance (I sat ) and off-resonance (I o ) saturation. Only well-resolved resonances with a signal-to-noise ratio [10 were analyzed. Chemical shift perturbations and cross-relaxation results were mapped onto OSCP structures and visualized using Pymol. 23 
RESULTS
Mapping the Binding of 1 to OSCP120 Using Chemical Shift Perturbation
In a first group of studies, we attempted chemical shift perturbation experiments using full-length, 15 N labeled OSCP (OSCP190) (Supporting Information Figure S1 ). However, the 2D HSQC spectra of OSCP190 were intractable due to aggregation identified by uniform reduction in NMR signal intensities. 16, 20 We subsequently prepared two truncated constructs for binding measurements. The first protein comprised residues 1-120 (OSCP120) and has been studied previously by NMR, and the second construct contained residues 1-145 (OSCP145). Titration of 1 into 15 N labeled OSCP120 at protein:ligand ratios of 1:1, 1:2, 1:4, and 1:8 led to chemical shift perturbations that suggest rapid exchange on the NMR timescale consistent with micromolar affinity, which agreed with previous data for Bz-423 (Figures 1 and 2  and Supplementary Information Table S1 ). 4 To assess the significance of the OSCP chemical shift perturbations, a second set of titration experiments were conducted using an analog lacking the naphthalene substituent 2. This analog possesses no activity in the F 1 F 0 -ATPase or cell-based assays, (data not shown) and therefore, we hypothesized should not to bind to the protein. Indeed, chemical shift perturbations were not observed in titration experiments with 2 ( Figure 2 ), indicating that the perturbations observed with 1 reflect specific binding interaction(s) that presumably are related to its inhibitory activity.
The chemical shift perturbations induced by 1 were distributed at different sites within the OSCP120 construct ( Figure 2 ). This observation suggests that 1 either binds at multiple sites and/or binding at one site causes conformational changes elsewhere in the protein. The range of intensities observed in OSCP120 suggests that the protein is highly flexible and potentially prone to ligand-induced (allosteric) conformational changes. In addition, previous studies of Bz-423 suggest a 1:1 stoichiometry upon binding to the F 1 F 0 -ATPase. 4 Collectively, these observations are consistent with ligand-induced conformational changes away from the binging site.
The chemical shift perturbations caused by 1 fall in three general regions of OSCP120; one is located between helices III, IV, and V (''shoulder'') and includes residues M51, L56, K65, V66, K75, K77, T82, S83, and N92; the second is located at the C-terminal tails of helices I and VI (''tail region'') and includes residues V111, R113, V116, C118, and T119; a third potential locus is located between the ''tail'' and ''shoulder'' regions ( Figure 3) . Interestingly, the latter region includes residues A25 and L88, which were previously shown to interact directly with the a peptide mimicking the F 1 domain of the F 1 F 0 -ATPase. 16, 20 To confirm the data obtained with OSCP120, we used a second OSCP construct comprising 145 amino acids (OSCP145). Unlike the OSCP190, this truncated protein did not aggregate and was amenable to chemical shift perturbation experiments with 1. Comparing the OSCP120 and OSCP145 spectra reveals that the majority of the OSCP120 resonances are not altered due to the additional 25 amino acids in the OSCP145 construct (Supplementary Information Figure S3 ). Not surprisingly, residues that showed significant differences between the two constructs were primarily located at the N-and C-termini. However, chemical shift differences were observed at helix V, which interacts with the F 1 peptide. 16 This region, which also undergoes perturbations with 1, may be subject to allosteric conformational perturbations that could be important in mediating OSCP interactions with the F 1 F 0 -ATPase F 1 domain. 4 Titration with 1 induced chemical shift perturbations in OSCP145, whereas 2 did not (Supplementary Information Figure  S4 ). Several resonances from the shoulder (M51, L56, K65, V66, K75, and N92) and middle region of the protein (A25, E36, L40, K47, I102, and F105) that overlaid in OSCP120 and OSCP145 showed similar perturbations with 1, including A25, which interacts with the F 1 helix (Supplementary Information Figure S3 ). Many residues in the shoulder region (E48, A52, K67, T73, S79, S83, E91, and R94) also showed larger perturbations with 1 in OSCP145 compared to OSCP120. By contrast, some of the perturbations observed in the ''tail'' (residues V116 and C118), middle (L88), and shoulder (T82) regions were less pronounced in OSCP145. Taken together, these data indicate that the shoulder region is the most probable binding site for 1 on OSCP.
Probing the OSCP Ligand-Binding Site by Cross-relaxation
Because chemical shift perturbations can arise from binding and/or conformational changes, cross-relaxation experiments were employed to localize the binding site of 1 on OSCP120. 24 For these studies, 2D HSQC spectra of OSCP following saturation of specific 1 H resonances in 1, and an equivalent reference spectrum with off-resonance (-50 ppm) saturation were measured. A reduction in OSCP resonance
The structure of OSCP120 (PDB ID# 2BO5) is shown with helices, termini, shoulder, and tail regions labeled.
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intensities in the on-resonance (I sat ) versus off-resonance (I o ) experiment indicates cross-relaxation processes due to proximity of ligand protons to OSCP amide protons resulting from a specific binding interaction. Although the cross-relaxation experiment is inherently insensitive since it recorded in 90% D 2 O to avoid saturation of the water resonance, and despite the limited solubility of OSCP, which further limited sensitivity, 32 well-resolved resonances with sufficient signal:noise were observed in the OSCP1201 complex. As shown in Figure 4 , significant intensity reductions ([20%) are observed for a number of residues. The majority of these residues (R41, K50, A52, V60, (7), (10) , and (24) and their average is shown in (a). The 32 residues that were measured are color coded according to intensity reductions with those showing no significant reduction in intensity colored in blue and resonances showing intensity reductions greater than the threshold cutoff of 0.8 colored in red. The same color scheme is used in (b) with labeled residues being those that showed significant intensity reductions in any of the three sets of cross-relaxation data. Residues that could not be monitored are colored in gray and the shoulder region is circled in (b).
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, S79, I86, and N87) fall in the ''shoulder'' region. Crossrelaxation to residues in the tail region (K28, K31, and V111) was also observed and V111 corresponds to a residue for which significant chemical shift perturbations upon titration of 1 were measured. However, this site is most likely cryptic and only present in the truncated OSCP constructs because the perturbations are diminished or otherwise significantly altered in OSCP145. Taken together, the chemical shift perturbation and cross relaxation studies are consistent with a unique binding site for 1 on the OSCP.
DISCUSSION
Inhibitors of the mitochondrial F 1 F 0 -ATPase are powerful tools for probing the structure and function of the enzyme and like Bz-423, some have therapeutic potential. [25] [26] [27] A diverse group of molecules inhibit the enzyme by binding within the F 1 domain. Representative compounds here include the antibiotics aurovertin and efrapeptin, phytochemicals like resveratrol, and the naturally occurring peptide inhibitor, IF1. Aurovertin binds to b TP and b E states of the enzyme and is thought to function by preventing closure of the interfaces necessary for catalytic cycling between subunit conformational states. 4, [28] [29] [30] [31] Efrapeptin interacts with the c and b E subunits where it can block recharging after catalysis. 28 Similarly, resveratrol inhibits the F 1 F 0 -ATPase by binding between the c and b TP subunits where it can block the rotation of the c subunit so that the catalytic cycle cannot progress. 32 IF1 inhibits ATP hydrolysis when the ability of the enzyme to synthesize ATP is compromised. IF1 is thought to function by hindering the closure of the a DP -b DP catalytic interface thereby blocking ATP hydrolysis. 33 Several molecules such as the macrolide oligomycin inhibit the F 1 F 0 -ATPase by binding to the embedded F 0 domain. 8 Biochemical studies suggest that oligomycin binding blocks the flow of protons through the c-subunit. Here, we used NMR spectroscopy to investigate binding of a water-soluble Bz-423 analog to OSCP constructs of varying length in an effort to define the binding site for these inhibitory benzodiazepines on the protein. The chemical shift perturbation data on both OSCP120 and OSCP145 together with crossrelaxation data for OSCP120 suggest that 1 most likely binds to the shoulder region in a pocket defined by residues M51, L56, K65, V66, K75, K77, and N92. The peak intensities of unbound OSCP120 suggest that both the shoulder and tail regions are more flexible relative to the rest of the protein, potentially allowing for local rearrangements to occur upon ligand binding (data not shown). While we cannot rule out a possible secondary binding site in OSCP120 involving the tail region, this interaction was diminished in OSCP145, indicating that interactions at this site are not likely relevant and probably result as a consequence of the truncation only present in the 120-amino acid long OSCP construct.
Several residues show chemical shift perturbations in the titration experiments but no significant cross-relaxation, which is most consistent with conformational changes on binding to 1. These residues include A25 and L88, which are thought to directly interact with the F 1 .
16,34 L88 along with other residues in its vicinity also shift when comparing free OSCP120 and OSCP145, even though the 25 amino acids are added to the C-terminal end of OSCP145. On the basis of the NMR structure of OSCP120, L88 is distant from the additional 25 amino acids. These data further support the hypothesis that this region of the OSCP is susceptible to conformational changes, which may be important for the function of the protein in the fully assembled enzyme and the activity of Bz-423 like inhibitors.
On the basis of our data, we propose an allosteric model for the inhibitory action of 1. Binding of 1 to the shoulder Another group of benzodiazepines have been reported that are structurally similar to Bz-423. 35 Unlike Bz-423, these compounds selectively inhibit ATP hydrolysis catalyzed by the mitochondrial F 1 F 0 -ATPase and may have use as antiischemia drugs. Preliminary studies suggest that these benzodiazepines also function through binding to the OSCP. 36 Together, these data highlight the important role the OSCP plays in regulating both the synthetic and hydrolytic the function of the mitochondrial F 1 F 0 -ATPase. A better understanding of how these compounds interact with the OSCP and inhibit the enzyme should assist in further elucidating the function of the OSCP and may also provide additional opportunities for drug discovery.
